These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12831592)

  • 21. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
    Kwan I; Bhattacharya S; McNeil A; van Rumste MM
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005289. PubMed ID: 18425917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro fertilization and the ovarian hyperstimulation syndrome.
    MacDougall MJ; Tan SL; Jacobs HS
    Hum Reprod; 1992 May; 7(5):597-600. PubMed ID: 1639974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries.
    Agrawal R; Conway G; Sladkevicius P; Tan SL; Engmann L; Payne N; Bekir J; Campbell S; Jacobs H
    Fertil Steril; 1998 Oct; 70(4):651-8. PubMed ID: 9797093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile.
    Papanikolaou EG; Tournaye H; Verpoest W; Camus M; Vernaeve V; Van Steirteghem A; Devroey P
    Hum Reprod; 2005 Mar; 20(3):636-41. PubMed ID: 15576388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of IVF pregnancies following severe OHSS.
    Raziel A; Schachter M; Friedler S; Ron-El R
    Reprod Biomed Online; 2009 Jul; 19(1):61-5. PubMed ID: 19573292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity.
    Shrivastav P; Nadkarni P; Craft I
    Hum Reprod; 1994 May; 9(5):812-4. PubMed ID: 7929727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
    Atkinson P; Koch J; Ledger WL
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures.
    Rizk B; Smitz J
    Hum Reprod; 1992 Mar; 7(3):320-7. PubMed ID: 1587936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consensus statement on prevention and detection of ovarian hyperstimulation syndrome.
    Boothroyd C; Karia S; Andreadis N; Rombauts L; Johnson N; Chapman M;
    Aust N Z J Obstet Gynaecol; 2015 Dec; 55(6):523-34. PubMed ID: 26597569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical outcomes of fresh versus cryopreserved-thawed embryo transfer in high-risk patients with ovarian hyperstimulation syndrome].
    Chen H; Wang B; Xu ZP; Sun HX
    Zhonghua Nan Ke Xue; 2014 Nov; 20(11):1008-11. PubMed ID: 25577837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis.
    Smith LP; Hacker MR; Alper MM
    Fertil Steril; 2009 Dec; 92(6):1953-9. PubMed ID: 18976762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos.
    D'Angelo A
    Semin Reprod Med; 2010 Nov; 28(6):513-8. PubMed ID: 21082511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.